CFTR
- 抑制剂选择性比较
- 溶解性比较
目录号 | 产品目录 | 溶解度(25°C) | ||
---|---|---|---|---|
水 | DMSO | 酒精 | ||
S6003 | Ataluren (PTC124) | <1 mg/mL | 57 mg/mL | <1 mg/mL |
S7139 | CFTRinh-172 | <1 mg/mL | 82 mg/mL | <1 mg/mL |
S7329 | IOWH032 | <1 mg/mL | 100 mg/mL | <1 mg/mL |
S8094 | GlyH-101 | <1 mg/mL | 98 mg/mL | <1 mg/mL |
S1144 | Ivacaftor (VX-770) | <1 mg/mL | 78 mg/mL | <1 mg/mL |
S8698 | GLPG1837 | <1 mg/mL | 69 mg/mL | 5 mg/mL |
S1565 | VX-809 (Lumacaftor) | <1 mg/mL | 90 mg/mL | 6 mg/mL |
S7059 | Tezacaftor (VX-661) | <1 mg/mL | 100 mg/mL | <1 mg/mL |
- CFTR抑制剂(8)
- 新CFTR产品
产品目录 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S6003 |
Ataluren (PTC124)Ataluren (PTC124)选择性诱导核糖体转录通读,但不影响正常的终止密码子,在HEK293细胞中EC50为0.1 μM,可以治疗nonsense mutations (如CFTR无义突变引起的CF)造成的家族遗传性疾病。 Phase 3。 |
![]() ![]() Effect of systemic ataluren treatment on mice with the Pax6Sey+/- phenotype. The black arrowhead indicates the lenticular stalk; the black arrow indicates the cornea; and the asterisk indicates the ciliary margin. WT, Pax6+/+; Mt, Pax6Sey/+; L, lens; r, retina. Original magnification, x5.
|
|
S7139 |
CFTRinh-172CFTRinh-172是电势差不依赖性的选择性CFTR抑制剂,Ki为300 nM,对于MDR1,ATP敏感性钾离子通道或者一系列的转运蛋白没有效果。 |
![]() ![]() CFTR attenuated ox-LDL-induced NF-
|
|
S7329 |
IOWH032IOWH032是一种合成的CFTR抑制剂,在CHO-CFTR细胞测定中, IC50为1.01 μM。 Phase 2。 |
||
S8094 |
GlyH-101GlyH-101是一种选择性且可逆的CFTR抑制剂,其Ki为4.3 μM。 |
||
S1144 |
Ivacaftor (VX-770)Ivacaftor (VX-770)是一种CFTR的选择性增强剂,靶向作用于G551D-CFTR和F508del-CFTR,在fisher大鼠甲状腺细胞中EC50分别为100 nM和25 nM。 |
![]() ![]() (A) CFTR Western blot of normal (NL) and CF HBE cultures treated with VX-809 (5 uM) ± VX-770 (5 uM) for 48 hours. “*” indicates the mature, complex glycosylated form of CFTR, band C; “•” indicates the immature band B. (B) Turnover of rescued ΔF508 in BHK-21 cells. ΔF508 was rescued at 27°C in the presence of VX-809 ± VX-770 for 24 hours. After adding cycloheximide (200 ug/ml, 37°C), cells were lysed at the indicated times and analyzed by Western blotting.
|
|
S8698New |
GLPG1837GLPG1837是新型的CFTR增效剂,对F508del的EC50为3 nM。相较于Ivacaftor,它对具有III类突变的CFTR突变体具有增强效应。 |
||
S1565 |
VX-809 (Lumacaftor)VX-809 (Lumacaftor)通过促进突变型CFTR(F508del-CFTR)的成熟,从而纠正囊性纤维症中常见的CFTR突变,在fisher大鼠甲状腺细胞中EC50为0.1 μM。Phase 3。 |
![]() ![]() RAF1 and CAMKK1 single siRNA validation in flow cytometry. RAF1 and CAMKK1 single Dharmacon ON-TARGETplus siRNAs with or without VX-809 treatment. Measured surface CFTR fluorescence with a BD Accuri flow cytometer with Intellicyt HTFC. The grayed out region represents VX-809s average surface fluorescence. VX-809 + siRNA significance is shown from VX-809 negative control. Data are shown as mean ± SEM (3−4 replicates). One-way ANOVA with multiple comparison for significant changes from VX-809 neg. ctrl (0 nM) (red P-values). ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05.
|
|
S7059 |
Tezacaftor (VX-661)Tezacaftor (VX-661)是第二个F508del CFTR校正药物,协助CFTR蛋白到达细胞表面。Phase 2。 |
![]() ![]() (B)ΔISC response to forskolin observed in VX-661-treated CF HBE cells (*P = 0.0021, VX661 vs. vehicle) was prevented by chronic VX-770 treatment and significantly different from VX-661-treated cells (#P=0.0126, VX661 vs. VX661+VX770). (C) The response to CFTR inh-172 that was observed in VX-661-treated cells (*P = 0.0111, VX661 vs. vehicle) was significantly decreased in VX809+VX770 treated cells (#P = 0.0038, VX661 vs. VX661+VX770). Primary CF HBE cultures (ΔF508/ΔF508) were derived from 3 different patients, and 3-4 replicates were performed per patient.
|